CTLA4 and neoplasm: (ICIs), such as anti-PD-1 and anti-CTLA-4, reawaken T cells that have been inhibited by the tumor microenvironment, thereby reinstating anti-tumor immunity and possibly averting latent tumor cells from evading immune surveillance and triggering metastasis [238,239,240,241].